Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study
The safety profile of durvalumab after radiotherapy was consistent with PACIFIC (durvalumab after chemoradiotherapy). Efficacy across cohorts was encouraging. Some patients may achieve or maintain molecular remission with durvalumab even after palliative radiotherapy. Durvalumab following radiotherapy may be a potential treatment option in a frailer, older, chemotherapy-ineligible population.
Authors
- I. Toledano
- G. Wetherill
- I. Diaz Perez
- K. Foroutanpour
- Francesco Agustoni (ORCID: https://orcid.org/0000-0002-4334-1230)
- Andrea Riccardo Filippi (ORCID: https://orcid.org/0000-0001-7159-7869)
- Paolo Borghetti (ORCID: https://orcid.org/0000-0001-7275-7908)
- Sylvie Van Hulst
- Robert Mróz (ORCID: https://orcid.org/0000-0002-5826-7395)
- D. Cortinovis
- Chiara Bennati (ORCID: https://orcid.org/0000-0002-2970-6483)
- Rafał Dziadziuszko (ORCID: https://orcid.org/0000-0001-8080-9843)
- Giuseppe Tonini (ORCID: https://orcid.org/0000-0003-4442-8677)
- Angelo Delmonte (ORCID: https://orcid.org/0000-0001-9065-6123)
- Sergiusz Nawrocki (ORCID: https://orcid.org/0000-0001-6225-6528)
- Nefeli Georgoulia
- Carlo Genova (ORCID: https://orcid.org/0000-0003-3690-8582)
- Zhen Zhu (ORCID: https://orcid.org/0000-0002-1640-3029)
- Diane Kowalski
- Jean-Baptiste Paoli
- M.R. García Campelo
Institutions
- AstraZeneca (United Kingdom) (GB)
- Medical University of Białystok (PL)
- Università Campus Bio-Medico (IT)
- University of Pavia (IT)
- Ospedale "Santa Maria delle Croci" di Ravenna (IT)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Hôpital privé Clairval (FR)
- Azienda Ospedaliera San Gerardo (IT)
- Clinique Clémentville (FR)
- Campus Bio Medico University Hospital (IT)
- Ospedale Policlinico San Martino (IT)
- AstraZeneca (United States) (US)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Policlinico San Matteo Fondazione (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- University of Warmia and Mazury in Olsztyn (PL)
- Université de Nîmes (FR)
- University of Milano-Bicocca (IT)
- Gdańsk Medical University (PL)
- University of Brescia (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-08-21
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105560
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Teva Pharmaceutical Industries
- Regeneron Pharmaceuticals
- Les Laboratories Pierre Fabre
- BeiGene
- Ministero della Salute
- PharmaMar
- Ipsen
- Genentech
- Cilag